Get the Stockscreener App
2.69
2.89%
-0.08
Adc Therapeutics Sa stock is traded at $2.69, with a volume of 668.86K.
It is down -2.89% in the last 24 hours and up +0.75% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$2.77
Open:
$2.72
24h Volume:
668.86K
Relative Volume:
0.90
Market Cap:
$266.79M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-0.9119
EPS:
-2.95
Net Cash Flow:
$-121.90M
1W Performance:
-17.99%
1M Performance:
+0.75%
6M Performance:
+60.12%
1Y Performance:
-12.09%
1-Day Range:
$2.59
$2.74
1-Week Range:
$2.59
$3.30
52-Week Range:
$1.05
$3.97
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
2.69 | 310.96M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
Is ADC Therapeutics SA stock overvalued or undervaluedPost Market Opportunities With High Returns - jammulinksnews.com
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - StreetInsider
ADC Therapeutics Makes Grants To New Employees Under Inducement Plan - Barchart.com
Should I hold or sell ADC Therapeutics SA stock in 2025Stock Strategy Review For Beginners - jammulinksnews.com
What is ADC Therapeutics SA company’s growth strategyPost Market Trend Scanner For Smart Trading - jammulinksnews.com
How volatile is ADC Therapeutics SA stock compared to the marketReal Time Guidance From AI Tools - jammulinksnews.com
Can volume confirm reversal in ADC Therapeutics SAReal-Time Analysis With Entry Targets In Progress - metal.it
What are the latest earnings results for ADC Therapeutics SAExpert Picks Guidance For 2025 - jammulinksnews.com
ADC Therapeutics (ADCT) to Release Quarterly Earnings on Tuesday - MarketBeat
How ADC Therapeutics SA stock performs during market volatilityTarget Return Focused Trade Insights Shared - metal.it
ADC Therapeutics SA Price Targets Raised After ReboundWeekly Watchlist of High Movers Released - metal.it
ADC Therapeutics SA Breaks Losing Streak — Is the Trend ReversingTrade Setups With Clear Risk Limits Highlighted - beatles.ru
Neuroendocrine Tumors Clinical Trials, Companies, - openPR.com
Neuroendocrine Tumors Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli L - Barchart.com
ADC Therapeutics SA Shows Risk Reward Favoring UpsideExit Ready Momentum Stock Watchlist Expanded - metal.it
Does ADC Therapeutics SA stock perform well during market downturnsEarnings Report Insights With Low Risk - jammulinksnews.com
How strong is ADC Therapeutics SA company’s balance sheetRetirement Planning Forecasts Backed By Experts - jammulinksnews.com
What is the dividend policy of ADC Therapeutics SA stockHigh-octane financial growth - jammulinksnews.com
What are ADC Therapeutics SA company’s key revenue driversExtraordinary market timing - jammulinksnews.com
How does ADC Therapeutics SA generate profit in a changing economyAchieve rapid portfolio growth with smart picks - jammulinksnews.com
What catalysts could drive ADC Therapeutics SA stock higher in 2025Extraordinary earning power - jammulinksnews.com
What is the risk reward ratio of investing in ADC Therapeutics SA stockGet daily expert analysis on top stocks - jammulinksnews.com
What makes ADC Therapeutics SA stock price move sharplyHigh Return Intraday Picks - metal.it
Why ADC Therapeutics SA stock attracts strong analyst attentionFree Stock Market Query - Newser
ADC Therapeutics SA Company Revenue and Profit Trends: A Deep DiveHigh Reward Risk Balanced Trading - Newser
Sectors Driving Future Growth for ADC Therapeutics SA StockLong Term Secure Gain Stocks - Newser
Adc Therapeutics Sa shares fall 1.83% after-hours following Janux Therapeutics' R&D Day press release. - AInvest
Is ADC Therapeutics SA a good long term investmentHigh-yield market plays - PrintWeekIndia
What analysts say about ADC Therapeutics SA stockExceptional market performance - PrintWeekIndia
What drives ADC Therapeutics SA stock priceBreakout stock performance - jammulinksnews.com
ADC Therapeutics SA Stock Analysis and ForecastExplosive portfolio gains - jammulinksnews.com
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):